Bristol-Myers Squibb Company
Lawrence Township, NJ
- UEI
- UFGKB2B71N12
- CAGE
- 4K2D9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
L52ANKRJYPL2
-
Parent
L52ANKRJYPL2
- SAM.gov registration date
- Physical address
- 3401 Princeton Pike, Lawrenceville, NJ 08648, USA
- Website
- bms.com
- Founded
- 1858
- Employees
- 10K-50K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $22,082 |
| FY2026 | $7,486,695 |
| FY2025 | $7,291,703 |
| FY2024 | $3,446,476 |
| FY2023 | $947,212 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $7,486,139 | |
| 2 | Department of Justice | $22,639 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Centocor Ortho Biotech Inc. | Horsham, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| CSL Behring L.L.C. | King of Prussia, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Ferring Pharmaceuticals Inc. | Parsippany-Troy Hills, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| ELI Lilly And Company | Indianapolis, IN | 325412 Pharmaceutical Preparation Manufacturing |
| Gilead Sciences Inc. | Foster City, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, supplies specialty oncology and immunomodulatory pharmaceuticals to the Department of Veterans Affairs as a prime contractor on a full-and-open basis, with no small business set-asides. The company is a large for-profit global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, specializing in chimeric antigen receptor (CAR) T cell therapies, hematologic malignancy treatments, and immunotherapy products.
Bristol-Myers Squibb's federal work concentrates almost entirely on the VA healthcare system, where it has received 120 prime awards totaling $40.93 billion in combined potential value over the past five years, with a sharp acceleration since 2024. The customer footprint is dominated by Veterans Integrated Service Networks: VISN 9 accounts for 50 awards valued at $14.1 million combined potential value, VISN 5 holds 38 awards at $2.3 million, and VISN 12 anchors the dollars at $37.97 billion combined potential value. The portfolio splits dramatically between the dollar concentration (VISN 12 alone represents 93% of combined potential value) and transaction volume (VISN 9 and VISN 5 drive 88% of award counts but represent only about 4% of dollars). This tension reflects Bristol-Myers Squibb's role as holder of two massive blanket purchase agreements alongside dozens of small, high-value individual patient delivery orders.
Bristol-Myers Squibb holds position on the GSA Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB), a multiple-award IDIQ vehicle with a $26.4 billion ceiling through April 30, 2029, awarded to Bristol-Myers Squibb on May 1, 2024. Against this vehicle, the company has received 152 task orders valued at $2.96 billion combined potential value. Within the FSS framework, Bristol-Myers Squibb also holds two large single-award blanket purchase agreements: one with VISN 15 for REVLIMID and POMALYST (ceiling $87.6 million through December 31, 2026) and another with the National Acquisition Center covering CAMZYOS, POMALYST, and THALOMID (ceiling $2.85 billion through January 15, 2027).
Representative capability work includes multiple delivery orders for BREYANZI (lisocabtagene maraleucel), a CAR T cell therapy for non-Hodgkin lymphoma, with single-unit valuations in the $310,000 to $364,000 range across VISN 9 delivery orders; ABECMA (idecabtagene vicleucel) for multiple myeloma and hematologic malignancies, similarly priced in the $314,000 to $338,000 range; REVLIMID (lenalidomide) and POMALYST (pomalidomide) for multiple myeloma and immunomodulatory treatment, supplied in multiple strength formulations through both individual delivery orders and the BPAs; and CAMZYOS (mavacamten) for hypertrophic cardiomyopathy. Thalidomide appears in lower-value orders, typically $5,814 to $11,977 per delivery. Awards are firm fixed-price with no set-aside designation and performance is centered on the company's Lawrenceville, New Jersey facility, with distribution through Memphis, Tennessee and VA medical centers nationwide.
Activity has grown sharply: one award in 2022, four in 2023, nineteen in 2024, twenty-four in 2025, and sixty in 2026 year-to-date. Within the next twenty-four months, six awards totaling $2.1 million in combined potential value reach ultimate completion, representing recompete exposure primarily in the smaller individual delivery orders rather than the large BPA or FSS vehicles. The company competes entirely under full-and-open procurement without set-aside categories, reflecting its position as a large manufacturer with no SBA designations. The award portfolio is categorized under NAICS 325412 (Pharmaceutical Preparation Manufacturing) across 120 awards and PSC 6505 (Drugs and Biologicals) across 118 awards, confirming the tight focus on specialty pharmaceutical supply to the VA oncology and hematology treatment mission.
Quick answers
Is Bristol-Myers Squibb Company registered in SAM.gov?
Yes. Bristol-Myers Squibb Company's SAM.gov registration is active through June 15, 2027.
What is Bristol-Myers Squibb Company's CAGE code?
Bristol-Myers Squibb Company's CAGE code is 4K2D9, and its Unique Entity ID (UEI) is UFGKB2B71N12.
Which contract vehicles does Bristol-Myers Squibb Company hold?
Bristol-Myers Squibb Company holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Bristol-Myers Squibb Company received in federal contracts?
Federal contracts obligated $7,291,703 to Bristol-Myers Squibb Company in fiscal year 2025 and $19,194,168 in fiscal years 2023 through 2027.
How does Bristol-Myers Squibb Company rank among federal contractors?
Bristol-Myers Squibb Company ranked #29 in NAICS 325412, #38 in PSC 6505 and #41 in NAICS 3254 in FY2025.
What is Bristol-Myers Squibb Company's most recent federal award?
Bristol-Myers Squibb Company's most recent federal contract award is Iberdomide HCL 1MG (36C26127F0037), from Veterans Integrated Service Network 21 (VHA), on November 2, 2026.
On GovTribe
See Bristol-Myers Squibb Company's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors